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Abstract
The Roussel Uclaf Causality Assessment Method (RUCAM) was developed to quantify the
strength of association between a liver injury and the medication implicated as causing the injury.
However, its reliability in a research setting has never been fully explored. The aim of this study
was to determine test-retest and interrater reliabilities of RUCAM in retrospectively-identified
cases of drug induced liver injury. The Drug-Induced Liver Injury Network is enrolling well-
defined cases of hepatotoxicity caused by isoniazid, phenytoin, clavulanate/amoxicillin, or
valproate occurring since 1994. Each case was adjudicated by three reviewers working
independently; after an interval of at least 5 months, cases were readjudicated by the same
reviewers. A total of 40 drug-induced liver injury cases were enrolled including individuals treated
with isoniazid (nine), phenytoin (five), clavulanate/amoxicillin (15), and valproate (11). Mean ±
standard deviation age at protocol-defined onset was 44.8 ± 19.5 years; patients were 68% female
and 78% Caucasian. Cases were classified as hepatocellular (44%), mixed (28%), or cholestatic
(28%). Test-retest differences ranged from −7 to +8 with complete agreement in only 26% of
cases. On average, the maximum absolute difference among the three reviewers was 3.1 on the
first adjudication and 2.7 on the second, although much of this variability could be attributed to
differences between the enrolling investigator and the external reviewers. The test-retest reliability
by the same assessors was 0.54 (upper 95% confidence limit = 0.77); the interrater reliability was
0.45 (upper 95% confidence limit = 0.58). Categorizing the RUCAM to a five-category scale
improved these reliabilities but only marginally.
Conclusion—The mediocre reliability of the RUCAM is problematic for future studies of drug-
induced liver injury. Alternative methods, including modifying the RUCAM, developing drug-
specific instruments, or causality assessment based on expert opinion, may be more appropriate.
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Identifying drug-induced liver injury (DILI) is a major clinical challenge.1 Unlike many
other medical conditions, no single test or biochemical signal exists to establish a definitive
diagnosis. This diagnostic dilemma is heightened by the fact that DILI can mimic virtually
all known forms of acute and chronic liver disease. Any confirmation of suspected DILI
requires that all the other plausible causes of liver disease be excluded; for example:
infection with hepatitis viruses A, B, and C; alcoholic and autoimmune hepatitis; or
ischemic or congestive hepatopathy. However, attention must also be directed to the pattern
of liver test abnormalities, the duration of latency to symptomatic presentation, the presence
or absence of features suggestive of immune-mediated hypersensitivity, and the response to
drug withdrawal and rechallenge.2-5 Thus, unlike many other disease areas, DILI is
diagnosed primarily by the clinical judgment of the attending physician and is frequently
based on “guilt by association.”6
Two instruments that have been developed to quantify the strength of association between
the liver injury and the implicated medication include the Roussel Uclaf Causality
Assessment Method (RUCAM)7,8 and the Maria and Victorino clinical scale.9 The RUCAM
is composed of seven different criteria; including: the time to onset, clinical course, risk
factors, concomitant drugs, non-drug-causes, published information on hepatotoxicity, and
the response to any re-administration. The RUCAM score ranges from −8 to + 14, with
higher values signifying a greater degree of association. The RUCAM was developed on an
ad hoc basis by consensus opinion among hepatotoxicity experts. Although it appears to be
superior to the Maria and Victorino scale10 and is widely used by the pharmaceutical
industry, a number of shortcomings have emerged. There are no explicit instructions on how
to interpret and score the individual components, the defining criteria are somewhat dated,
the scales for the different components are rather arbitrary, and the final score is not
intuitive. Despite these shortcomings, the RUCAM has been used to identify DILI events in
case studies of prescription drugs,11-13 herbal medications,1,15 epidemiological studies,16-18
clinical trials,19 and genotyping studies.20
The RUCAM was validated using patients who had been rechallenged with the implicated
medication.8 However, its reliability in a clinical research setting has never been fully
explored. In this work, we report the results of an empirical investigation of the test-retest
and interrater reliability of the RUCAM. Specifically, the following questions were posed:
(1) Is there consistency in the RUCAM score when it is repeated over an interval of time?
(2) Is there consistency in the RUCAM score across independent reviewers? and (3) What
are the test-retest and interrater reliability coefficients of this instrument?
Materials and Methods
The Drug-Induced Liver Injury Network
In 2003, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
established the Drug-Induced Liver Injury Network (DILIN) to advance understanding and
research into DILI.21 The network is composed of five clinical sites and their affiliates: a
data coordinating center, the NIDDK project office, a biosample repository, and a central
liver histopathology core. The network is charged with identifying large numbers of well-
defined DILI cases and to collect clinical data and biological samples for the study of
pathogenesis.
The Idiosyncratic Liver Injury Associated with Drugs Study
One of the DILIN studies is the Idiosyncratic Liver Injury Associated with Drugs (ILIAD)
study. ILIAD is a retrospective study enrolling patients who have experienced significant
DILI in the recent past. The protocol was approved by the Institutional Review Boards at the
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participating institutions and is registered at Clinical-Trials.gov. To be eligible, patients
must have been alive at the time of the clinic visit; the implicated medication must have
been either isoniazid, phenytoin, combination clavulanic acid/amoxicillin, or valproic acid;
the date of onset of the qualifying DILI event must have been on or after January 1, 1994;
and there must be sufficient documentation that a causality determination can be made.
Individuals less than 2 years old at the time of study enrollment were excluded due to blood
volume requirements. January 1, 1994 was chosen because it is considered to be the limit at
which accurate, relevant, and complete medical records and charts would be available for
abstraction, as well as the time when diagnostic testing for acute and chronic hepatitis C
virus infection became widely available in the United States. The four drugs were targeted
because they cause severe DILI at a sufficiently high rate compared to other drugs, have a
characteristic clinical pattern of injury, and are typically administered to reasonably healthy
patients not concurrently receiving other drugs more likely to be hepatotoxic. This allows
causality to be assessed in a manner relatively uncontaminated by extraneous factors, and
might therefore be considered as the “best-case scenario” for assessing the reliability of the
RUCAM.
Cases were enrolled in the study if there was sufficient evidence that the liver injury was
causally associated with the implicated drug as judged by the clinical experience of the site
principal investigator (PI). The qualifying criterion for notable liver dysfunction was a total
serum bilirubin level >2.5 mg/dL on at least one occasion for isoniazid, phenytoin, and
clavulanic acid/amoxicillin; the criteria for valproate were a compatible symptomatic
clinical presentation severe enough to prompt hospitalization, with evidence of liver
dysfunction; that is, international normalized ratio >1.5 or alanine aminotransferase >3× the
upper limit of normal, and/or characteristic abnormalities seen on liver biopsy. In all
instances, the date of “onset” was defined as the first date on or after starting the implicated
medication when the corresponding criterion was detected recognizing that the true date of
onset is often unknown.
All enrolled patients reviewed and signed an informed consent document. Some information
was collected directly from patients using a telephone or personal interview including
demographic information, alcohol consumption history, vital status and demographics of all
biological parents, siblings, and children, together with a history of prior liver problems.
Detailed clinical data were abstracted from all available medical records including medical
conditions and illnesses; detailed exposure to the implicated medication as well as other
prescription and herbal medications; signs, symptoms and extra-hepatic manifestations
during the liver injury; detailed liver-related biochemical tests including serum alanine
aminotransferase, aspartate aminotransferase, alkaline phosphatase, bilirubin, international
normalized ratio, and prothrombin time; other laboratory assays as available including the
complete blood count with differentials, serum albumin, protein and creatinine levels; the
results from serological and other assays and any imaging studies; and whether the patient
was rechallenged with the DILI medication. Data were recorded on case report forms
(CRFs), and once data validation was complete, the case was made ready for the
adjudication process.
Causality Adjudication Process
Causality adjudication was performed by a committee of DILIN investigators. The
committee met monthly by teleconference and consisted of the PIs and coinvestigators at the
five clinical sites as well as members from the data coordinating center; and the NIDDK.
For each case, a subset of the CRF containing data directly relevant to the adjudication
process (i.e., the “CRF Subset”) was extracted from the database and made available to
reviewers. Additionally, a two-page clinical narrative was compiled by the site investigator
contributing the case. It provided a summary of the clinical/medical history of the case, but
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focused on supplemental information that was difficult to capture in a CRF. This included a
succinct summary of the presentation, laboratory values, diagnostic studies, and the rationale
for attributing the event to drug-induced liver injury.
The clinical narrative and CRF subset were provided to three reviewers. The first was the PI
at the DILIN clinical site who enrolled the case and completed the clinical narrative. The
other two reviewers were selected at random from other committee members. They came
from distinct clinical sites and from sites other than that enrolling the case. The three
reviewers worked independently of each other and completed the RUCAM instrument.
None of the reviewers had used the RUCAM instrument routinely prior to participating in
the study, and operating procedures were developed after consulting with one of the
RUCAM authors. The total score was derived using published criteria.7 This methodology
allows the reliability among the three reviewers to be evaluated. To evaluate test-retest
reliability, the entire process was repeated. That is, after a “washout” period of at least 5
months (mean = 343; range; 150 to 531 days), each case was reviewed by the same three
reviewers on a second occasion. Thus, each case was reviewed by three independent
reviewers on two separate occasions.
Statistical Methods
Simple descriptive statistics, that is mean ± standard deviation (SD), and frequency
distributions, were used to summarize the characteristics of the study population and the
liver injuries. They were also applied to the RUCAM score on each occasion and for the
difference between them. A Bland-Altman plot22 was applied to depict differences between
the two occasions. That is, for each case and each reviewer, the difference between the two
occasions was plotted against their average to determine if test-retest differences were
consistent throughout the range of the RUCAM score. To appreciate differences among the
three reviewers, the absolute values of the pairwise differences among the three reviewers
were derived. Then, the maximum among these pairwise differences, the maximum absolute
difference (MAD), was determined. A MAD value of 0 indicates complete agreement
among the three reviewers; a value of 1 indicates a case in which two reviewers agreed and
the third differed by only 1 point.
A mixed-effects regression model was applied to perform a formal reliability analysis. To
account for inherent variability among the cases, the following variables were included as
covariates: clinical site, age greater than or equal to 55 years, gender, any alcohol use,
hepatocellular versus cholestatic/mixed liver injury, time to onset, and the peak liver serum
enzyme values. Random effect terms included patient, reviewer, and the patient × reviewer
interaction, and reliability coefficients were derived from the corresponding variance
estimates.23 A reliability coefficient ranges from 0 to 1, with higher values signifying
greater reliability. Because interest is focused on whether the reliability achieves a minimum
threshold of acceptability, a one-sided upper 95% confidence limit (U95CL) was derived
using bootstrapping methods.24,25 Sample size calculations were performed26 to test the null
hypothesis that the reliability coefficient was greater than 0.65. Power was set to 80%.
Anticipating that the interrater reliability would in fact be 0.80, with three reviewers a
minimum sample of 40 participants was required.
Results
Patient Characteristics
The study was conducted with the first 40 patients enrolled in the ILIAD study including
nine cases of isoniazid, five cases of phenytoin, 15 cases of clavulanate/amoxicillin, and 11
cases of valproate hepatotoxicity. Table 1 provides their clinical characteristics. Mean (±SD)
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age at onset was 44.8 ± 19.5 years, ranging from 3.5 to 78.5; of these, 36% were 55 years of
age or older. A total of 68% of patients were female; 78% were Caucasian and 15% were
African-American. Of 40 patients, 11 (28%) reported a known history of pre-existing liver
disease including abnormal liver biochemical tests (three patients), chronic hepatitis C virus
infection (two patients), hemochromatosis (one patient), and unspecified cirrhosis (one
patient). Mean body mass index at DILI onset was 28.5 kg/m2, ranging from 16.0 to 51.1. A
total of 30% reported having at least one alcoholic beverage during the 1-month interval
prior to starting the implicated medication, and most reported 1-2 drinks per occasion (not
shown).
Severity of the Liver Injury
The mean (±SD) number of days from drug start to onset of liver injury was 156 ± 455;
however, this mean was heavily influenced by a small number of large values. The median
time to onset was 42.5 days. Of the 40 patients, 73% were hospitalized, most (63%) were ill
for several months, and 15% were prescribed prednisone. During the liver injury, all patients
experienced at least one symptom, including jaundice (73%), nausea (55%), dark urine
(50%), vomiting (35%), and abdominal pain (33%); 18% had extrahepatic manifestations.
Only one of 40 patients (2.5%) was re-challenged. Cases were characterized as being
cholestatic (28%), mixed (28%), or hepatocellular (44%) in presentation, based on the R-
ratio on the date of onset. Ultrasound of the liver was performed in 26 of 40 cases, and was
found to be abnormal in 15 (58%) patients. Ultimately, six patients (15%) required liver
transplantation. Mean (± SD) peak serum test results during the injury, by implicated drug,
are provided in Table 2, and reflect characteristic patterns of liver injury caused by these
drugs.
Site PI versus External Reviewers
Of the 120 scores expected on each occasion, 119 and 116 were available on the first and
second occasions, respectively. Missing reviews were due to investigators who left DILIN in
the intervening period or were otherwise unavailable. Preliminary analyses revealed a
significant difference between the site PI and the external reviewers as a group. After
adjusting for covariates, the RUCAM score (mean ± standard error) for the site PI was 7.2 ±
0.5 versus 6.4 ± 0.5 for the external reviewers (P = 0.007). We therefore distinguished
between these two groups in subsequent analyses.
Comparison Between the Two Occasions
Mean adjusted RUCAM scores (±standard error) on the two occasions were 6.4 ± 0.5 and
6.6 ± 0.5, respectively (P = 0.29). However, this overall result masked considerable
variability on a case-by-case basis. The difference between the two occasions pooled across
reviewers and patients is shown in Fig. 1A. Differences ranged from −7 to +8 with positive
differences largely offset by negative ones. Site PIs were less variable than the external
reviewers (Fig. 1B) with their test-retest differences ranging from −4 to + 6. Overall, there
was complete agreement in only 26% of cases, with differences greater than two or three
points in absolute value in 19% and 12% of cases, respectively. A Bland-Altman plot (Fig.
2) revealed that differences were roughly consistent throughout the range of the RUCAM
score, with perhaps smaller test-retest differences towards the lower end of the scale.
Comparisons across the Three Reviewers
On average, the MAD among the three reviewers was 3.1 on the first occasion and 2.7 on
the second occasion. However, much of this variability could be attributed to differences
between the site PI and the external reviewers. Figure 3 summarizes the MAD between the
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two external reviewers (only) on the two occasions. The MAD ranged from 0 to 7, with
average MADs of 2.0 and 1.3 on the first and second occasions, respectively.
Reliability Analysis
From the mixed-effects statistical model, the overall test-retest reliability was 0.54 (U95CL
= 0.77). The interrater reliability was 0.45 (U95CL = 0.58). Considering the site PIs only,
the test-retest reliability improved to 0.65 (U95CL = 0.84). Among the external reviewers,
however, the test-retest reliability was 0.43 (U95CL = 0.77), while the interrater reliability
was 0.46 (U95CL = 0.63).
The small samples sizes precluded performing separate analyses for each of the implicated
drugs. However, the reliability appeared to be lower for valproic acid. For example, test-
retest differences of one point or less in absolute value were observed in 65% of isoniazid
reviews, 60% of phenytoin reviews, and 64% of clavulanate/amoxicillin reviews, but in only
55% of those with valproic acid (data not shown). Severity of liver disease may have also
played a role. Combining patients with a prior liver injury and/or requiring liver transplant
(n = 17) revealed test-retest differences of one point or less in absolute value in 55% of
reviews. The corresponding number for less severe cases (n = 23) was 67%. Moreover, of
the seven components comprising the RUCAM, Question 2 (time course of the liver injury)
and Question 5 (potential nondrug causes) exhibited the greatest test-retest differences (not
shown). In particular, Question 5 ranges from −3 to +2 and gave rise to test-retest
differences ranging from −5 to +5. Both questions require the reviewers to interpret
complicated clinical information, and they might be more effective if they were split into
separate questions.
RUCAM as a Categorized Score
Benichou et al.8 suggested that the RUCAM could be collapsed into a five-category scale
with categories, highly probable (>8), probable (6-8), possible (3-5), unlikely (1-2), and
excluded (≤0). Pooling across reviewers and occasions (n = 235), cases were classified as
highly probable (15%), probable (53%), possible (24%), unlikely (3%), and excluded (4%).
The site PIs again attributed a significantly greater causality category than the external
reviewers (P = 0.009). The distribution of the test-retest differences is provided in Table 3,
and ranged from −3 to +2. Overall, there was complete agreement in 74 of 115 (64%) of
reviews, with a difference of one category or less in absolute value in 91% of reviews. Table
4 provides the MAD between the two external reviewers on each occasion. There was
complete agreement (MAD = 0) in only 50% and 63% of cases, respectively; MADs of one
point or less were observed in 95% and 90% of cases on the two occasions.
Using the categorized scale, the overall test-retest reliability was 0.51 (U95CL = 0.76); the
interrater reliability was 0.34 (U95CL = 0.49). Considering the site PIs only, the test-retest
reliability improved to 0.61 (U95CL = 0.81). Among the external reviewers, the test-retest
reliability was 0.54 (U95CL = 0.77), while the interrater reliability was 0.54 (U95CL =
0.59).
To gain a better appreciation of the clinical implication of this result, Table 5 presents a
cross-tabulation of the Reviewer A score versus the Reviewer B score on the categorized
RUCAM pooled across the two occasions. Thus, of the 11 reviews in which Reviewer A
scored the DILI case as highly probable, Reviewer B agreed in only five instances.
Similarly, of the 21 reviews in which Reviewer B scored the case as possible, Reviewer A
agreed in only six instances. Question 2 (time course of the liver injury) and to a lesser
extent Question 1 (time to onset) and Question 4 (concomitant drugs) were largely
responsible for the greatest interrater disagreements. In a research setting, this table might be
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collapsed further into a simple 2 × 2 table by combining the first two categories and the last
three categories to rule in or rule out a DILI case, respectively. Even when reduced to this
most basic level, however, there was complete agreement in only 58 of 78 reviews (74%).
Thus, the ability of the RUCAM to authenticate a DILI event in a clinical research or
practice setting is less than ideal.
Discussion
Although this study was conducted by hepatologists with good experience in hepatotoxicity,
the RUCAM largely failed to meet the minimum thresholds for a reliable instrument.
Discrepancies of three and four points in the continuous version and one point in the
categorized version seem rather small; however, reliability is concerned with variability
rather than bias. In this regard, there was considerable variability in the RUCAM between
the two occasions and among the three reviewers. Under the best-case scenario, the test-
retest reliability among the site PIs was only 0.65 while the interrater reliability among the
external reviewers was unacceptably low at 0.46. Typically, a test-retest reliability of 0.8
and interrater reliability of 0.6 are expected, and only the U95CL for the former exceeded its
threshold.
Multi-item questionnaires are frequently used in other clinical areas to quantify the level of
disease activity. These instruments also require clinical judgment, and it is instructive to
compare our results against the reliability coefficients of these questionnaires. For example,
test-retest reliabilities of 0.85 to 0.93 were reported for the Recent-Onset Arthritis Disability
Index27; 0.71 to 0.95 for the Dyspnea Management Questionnaire28; and 0.87 to 0.97 for the
Inflammatory Bowel Disease Questionnaire.29 Similarly, the interrater reliability of the
Pediatric Ulcerative Colitis Activity Index30 was reported as 0.87, while that of the Myositis
Assessment Scale31 was 0.89. Interestingly, a disease activity index was also developed
using a consensus process among clinical experts in idiopathic inflammatory myopathy.32
Even after an initial training series, however, interrater reliabilities of 0.32 to 0.74 were
observed.
There are a number of limitations to the generalizability of these results. First, the ILIAD
drugs are well known hepatotoxins and were selected largely for their known DILI
signatures. Cases were enrolled only if the site PI felt a priori that there was a significant
degree of association between the liver injury and the implicated drug. Moreover, the liver
injuries were severe: 73% of cases were hospitalized, many were jaundiced, and 6%
required liver transplantation. In effect, these are “classic” DILI cases, and compared to
other drugs, should have resulted in greater agreement over time and among the reviewers.
On the other hand, the study was conducted retrospectively, with cases going back to 1994.
Many medical records and charts for older cases were missing or incomplete, data on death,
fulminant hepatic failure, and dechallenge were not always available, and other competing
causes may not have been excluded completely. It will be of interest to see if the reliability
is greater with more complete data collected prospectively.
Lachin33 discussed the statistical implications of poor reliability in clinical research.
Specifically, the level of association between a measure with poor reliability and other
variables as assessed by correlation, regression, or analysis of variance is shrunk toward
zero, making it more difficult to declare statistical significance. Statistical power is reduced,
so that the sample size must be increased correspondingly. Sensitivity and specificity of the
instrument are also attenuated, giving rise to classification errors and impairing its utility to
serve as a diagnostic marker. This has significant implications for the RUCAM's ability to
detect DILI signals and declare DILI cases.
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There are two approaches to overcome these limitations. One is to categorize the instrument.
However, our analysis reveals that this maneuver improved matters only marginally. There
was complete agreement in only a small majority of cases, and the test-retest and interrater
reliabilities remained low. The other is to have m reviewers perform the evaluation
independently and take the average. Lachin33 showed that if ρ is the reliability coefficient of
a single assessment, the reliability of the average is given by, mρ/[1 + (m − 1) ρ]. With the
three independent reviewers in ILIAD, this would raise the interrater reliability from 0.46 to
0.71. This brings the reliability to a more acceptable range and is strongly recommended for
research purposes.
Site PIs tended to attribute greater causality score than the external reviewers, which raises
important issues. Because the site PI enrolled the case and was the “champion” of that case
in the Causality committee, he or she may have been more zealous in attributing the event to
a drug-induced liver injury. Alternatively, site PIs may have been more intimately familiar
with nuances of the cases not captured completely in the CRF subset and narrative,
selectively emphasizing certain components of the instrument. Either way, this suggests that
the RUCAM is a “subjective” instrument and casts doubt on its utility as an “objective”
measure of DILI causality. It also raises the possibility that causality should only be assessed
by reviewers at arm's length from the case. This might avoid bias, but from a reliability
perspective, this would be a mistake. The site PIs were consistently more reliable than the
external reviewers. Written instructions, criteria for competing causes, and evidence-based
revisions, pilot-tested in prospective cohorts, would go a long way toward overcoming these
limitations.
Smaller MADs among the three reviewers were observed on the second occasion compared
to the first. This may reflect accumulating experience and familiarity with the RUCAM as
time progressed. It may also reflect accumulating experience with the “gestalt” of the
monthly Causality Committee teleconferences. Nobody wants to be an outlier, and reviewers
may have become more adept at anticipating how their colleagues would weigh the evidence
and score the case. This weakens the assumption of reviewers working independently as
time progressed, and argues that special attention must be paid to this operating assumption.
Finally, there are many who would argue that because of its idiosyncratic nature, the gold
standard for adjudicating cases of DILI can only be the clinical judgment of expert
hepatologists. Indeed, DILIN is applying an expert opinion process in its clinical studies.
However, this is not practical in a clinical setting, and the reliability among practitioners is
likely to be lower. Thus, over the long term, priority should be given to developing an
authoritative, evidence-based causality instrument that would be easily accessible to the
clinical and research communities; for example, over the internet. In the interim,
modifications to the RUCAM, including improved instructions, updated criteria for
competing causes of liver injury, and a central reference for prior reports of hepatotoxicity,
are needed to improve its performance characteristics as an investigational tool.
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Abbreviations
CRF case report form
DILI drug-induced liver injury
DILIN Drug-Induced Liver Injury Network
ILIAD idiosyncratic liver injury associated with drugs
MAD maximum absolute difference
NIDDK National Institute of Diabetes and Digestive and Kidney Diseases
PI principal investigator
RUCAM Roussel Uclaf causality assessment method
SD standard deviation
U95CL upper 95% confidence limit
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Histogram of the within-reviewer differences from the first occasion to the second occasion.
(A) All reviewers. (B) Site PIs only.
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Bland-Altman plot of test-retest differences versus their mean. The purpose is to determine
if the test-retest differences were consistent throughout the range of the RUCAM score. This
would be reflected by a constant level of scatter about the reference line. Deviations form
this pattern suggests that consistency varies from one place to another in the scale and casts
doubt on its overall reliability.
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Histogram of the maximum absolute difference between the two external reviewers. (A)
First occasion. (B) Second occasion.
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Table 1
Characteristics of ILIAD Cases
Characteristics Mean ± SD or Percent*
Demographics:
 Age at DILI onset (years) (n = 39) 44.8 ± 19.5
 Age ≥55 years (n = 39) 35.9%
 Gender female 67.5%





 Prior history of a liver problem 27.5%
 Prior episode of jaundice 25.0%
 Prior reaction to a drug requiring doctor visit 35.0%
 BMI at DILI onset (kg/m2) (n = 39) 28.5 ± 8.3
 At least one alcoholic drink prior to taking drug 30.0%
 Days from drug start to onset (n = 38) 156 ± 455
 Hospitalized 72.5%
How long was the patient sick?
 A few days 5.0%
 One week 2.5%
 2-4 weeks 30.0%
 ≥1 month 62.5%
Prescribed prednisone 15.0%
Selected signs and symptoms:
 Jaundice 72.5%
 Nausea 55.0%
 Dark urine 50.0%
 Vomiting 35.0%
 Abdominal pain 32.5%
 Extrahepatic manifestations 17.5%
Rechallenged with DILI medication 2.5%
Type of liver injury (n = 39):†
 Hepatocellular (R ≥ 5) 44%
 Mixed (2 < R < 5) 28%
 Cholestatic (R ≤ 2) 28%
Diagnostic tests:
 Abnormal ultrasound (n = 26) 57.7%
 Abnormal abdominal CT (n = 17) 58.8%
 Abnormal abdominal MRI (n = 2) 100%
 Abnormal biopsy (n = 14) 100%
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Characteristics Mean ± SD or Percent*
Underwent liver transplantation 15.0%
*
Based on the complete sample of 40 DILI cases unless otherwise indicated.
†
R is defined as (ALT/ULN) ÷ (AP/ULN) at the time of onset. BMI, body mass index; CT, computed tomography; MRI, magnetic resonance
imaging.
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Table 2
Mean ± SD Peak Serum Tests Observed During the Liver Injury Expressed as a Multiple
of the ULN
Serum Test Isoniazid Phenytoin Clavulanate/Amoxicillin Valproate
AST 48.0 ± 28.5 36.9 ± 48.6 15.6 ± 25.8 16.1 ± 21.4
ALT 32.1 ± 13.3 20.7 ± 13.2 12.5 ± 23.2 14.3 ± 20.1
AP 2.7 ± 1.2 5.9 ± 9.1 4.0 ± 2.1 1.7 ± 1.1
Bilirubin 15.8 ± 9.7 10.9 ± 10.4 14.4 ± 14.6 6.7 ± 10.6
ULN, upper limit of normal; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AP, alkaline phosphatase.
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Table 3
Distribution of the Between-Occasion Difference in the Five-Category RUCAM Score
Difference External Reviewers Site PIs
Frequency (n = 77) Percent Frequency (n = 38) Percent
−3 3 3.9 0 0.0
−2 1 1.3 2 5.3
−1 12 15.6 4 10.5
0 49 63.6 25 65.8
1 9 11.7 6 15.8
2 3 3.9 1 2.6
The RUCAM is categorized as follows: highly probable (>8), probable (6-8), possible (3-5), unlikely (1-2), and excluded (≤0).
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Table 4
Maximum Absolute Difference Between the Two External Reviewers in the Five-Category
RUCAM Score by Occasion
MAD
Occasion 1 Occasion 2
Frequency (n = 40) Percent Frequency (n = 38) Percent
0 20 50.0 24 63.2
1 18 45.0 10 26.3
2 2 5.0 3 7.9
3 0 0.0 1 2.6
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